All In Biotech

Drug Trial Radar · NCT05111002

Lefamulin for M. Genitalium Treatment Failures

Lefamulin for Mycoplasma Genitalium Treatment Failures in the US

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

12

Actual

Start

Apr 22, 2022

Primary completion

Nov 30, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nabriva Therapeutics AG
First posted
Nov 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this drug study is to find out whether the antibiotic lefamulin (trade name Xenleta) will cure Mycoplasma genitalium infections that have not been cured by prior antibiotics while finding out whether it is more effective if the antibiotic doxycycline is taken first.

Conditions

  • Mycoplasma Genitalium Infection

Interventions

  • LefamulinDrug

    600mg tablet orally twice daily

  • DoxycyclineDrug

    100mg tablet orally twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants With Microbiologic CureTime frame: 21-28 days after completion of the lefamulin

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.